Medical Care, Vol. 45, No. 10, Supplement 2: Comparative Effectiveness and Safety: Emerging Methods (Oct., 2007), pp. S143-S148 (6 pages) Background: In observational research, propensity score ...

Background. Health services researchers are often interested in the effect of a treatment or a service in situations in which randomization is difficult or impossible. One useful alternative involves ...

Sorafenib is currently the only Food and Drug Administration–approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose ...

To inform continued development of the novel immune agent GEN-1, we compared ovarian cancer patients' end points from a neoadjuvant single-arm phase IB study with those of similar historic clinical ...